Oyster Point Pharma, Inc.   Report issue

For profit Phase 2 Phase 4
Founded: San Francisco CA United States (2015)
Status: Acquired by Viatris (2022) → now Mylan (2016)

Organization Overview

First Clinical Trial
2018
NCT03452397
First Marketed Drug
2021
varenicline (chantix)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

OYSTER POINT PHARMA | Oyster Point Pharma, Inc.

Active Ingredients

Marketed Drugs (1)

varenicline (chantix) (2021)

Drugs in Phase 4 Trials (1)

varenicline (chantix) (10 trials)

Drugs in Phase 2 Trials (1)

simpanicline (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Signs and Symptoms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 2